• SM-102: From Lipid Component to Design Strategy

  2026-09-22

  SM-102 is best understood not as a standalone formulation answer, but as a mechanistically informed design variable within mRNA lipid nanoparticles. By combining published machine-learning evidence, molecular interpretation, material-control practices, and translational decision criteria, researchers can use this ionizable lipid more strategically while avoiding overgeneralization from any single benchmark.

• Safe DNA Gel Stain for RNA and DNA Workflows

  2026-09-22

  Safe DNA Gel Stain supports sensitive DNA and RNA gel imaging while enabling blue-light visualization that can reduce UV exposure during cloning and nucleic acid recovery. This guide translates its specifications into practical agarose and acrylamide workflows, with troubleshooting for weak bands, background fluorescence, RNA smearing, and small-fragment detection.

• Romidepsin: HDAC2, Splicing, and PARP Assays

  2026-09-21

  Romidepsin (FK228) is a selective class I HDAC inhibitor for investigating chromatin regulation, HDAC2-dependent spliceosome stability, and PARP-inhibitor sensitivity. This article develops an assay-centered framework that connects epigenetic modulation to DNA-repair phenotypes in hepatocellular carcinoma research.

• Esculetin, CKLF1, and Post-Stroke Repair

  2026-09-21

  A 2025 study identifies CKLF1-mediated neutrophil infiltration as a mechanistic link between post-stroke inflammation and impaired neurological recovery. Using pharmacological, imaging, cellular, and genetic approaches, the researchers show that esculetin reduces inflammatory infiltration and improves structural, functional, and behavioral outcomes in a mouse photothrombotic stroke model.

• TAK1–YAP Control of Gastric Cancer Stem Cells

  2026-09-20

  The reference study identifies a mechanistic link between IL-6-induced TAK1 expression, cytoplasmic YAP stabilization, and the SOX2/SOX9 transcriptional program that supports gastric cancer stem-cell self-renewal and oncogenesis. Its combination of tissue profiling, molecular interaction analysis, and functional tumor models provides a framework for studying how inflammatory kinase signaling sustains cancer stemness.

• Safe DNA Gel Stain: Safer Gel Imaging

  2026-09-19

  Safe DNA Gel Stain is a DNA and RNA gel stain for fluorescent visualization in agarose and acrylamide gels. Its blue-light-compatible workflow can reduce reliance on UV exposure, while product-specific dilution, solvent, storage, and low-molecular-weight limitations should guide validation.

• Fingolimod (FTY720): A Causal Assay Framework

  2026-09-18

  Fingolimod (FTY720) can do more than model S1P biology: it can help investigators distinguish lymphocyte egress effects from magnetic T-cell retargeting. This article presents a causal assay framework for interpreting emerging in vivo CAR-T-mimicking systems without mistaking trafficking control for tumor-cell recognition.

• MroGCL Regulation of Early Prawn Spermatogenesis

  2026-09-18

  This 2024 study identified and functionally examined MroGCL, a germ cell-less homolog in the giant prawn Macrobrachium rosenbergii. Its expression profile and RNAi phenotype support a role in early spermatogenic regulation, while also revealing substantial animal-to-animal variation that limits claims of complete sterility.

• AO/PI Double Staining Kit for Rare-Cell QC

  2026-09-17

  The AO/PI Double Staining Kit provides a rapid cell viability assay that separates viable, apoptotic, and membrane-compromised cells by fluorescence. This article explains how to use Acridine Orange Propidium Iodide staining as a quality-control layer in rare-cell workflows, including circulating tumor cell capture, while defining its analytical limits.

• Cisplatin A8321: Reliable Cytotoxicity Assays

  2026-09-17

  A scenario-based guide to using Cisplatin (SKU A8321) in viability, proliferation, apoptosis, and chemotherapy resistance studies. It connects mechanism, solvent compatibility, assay controls, orthogonal readouts, and practical vendor selection to improve interpretability and workflow consistency.

• nor-Binaltorphimine dihydrochloride in Pain Assays

  2026-09-16

  Use nor-Binaltorphimine dihydrochloride to test whether κ-opioid receptor signaling controls pain laterality, persistence, or circuit-specific responses. This guide connects the reference study’s brain-to-spinal findings with practical stock preparation, behavioral design, receptor assays, and troubleshooting.

• Nicotinamide Riboside Chloride in RGC Research

  2026-09-16

  Learn how NIAGEN can be layered onto chemically defined retinal ganglion cell workflows to investigate NAD+ biology, oxidative metabolism, and stress resilience. This practical guide separates evidence from exploratory use, with formulation guidance, assay controls, and troubleshooting for metabolic and neurodegenerative disease models.

• PD-L1 Degradation in Myeloid Cells

  2026-09-15

  A 2025 Journal for ImmunoTherapy of Cancer study identifies PD-L1 recycling through CMTM6 as a therapeutically actionable process in myeloid cells. Its anti-PD-L1 antibody H1A redirected PD-L1 toward degradation, enhanced myeloid activation, expanded cytotoxic T-cell populations, and improved tumor control in preclinical models.

• Cyclodextrin Nano-Adsorbents for Uremic Toxins

  2026-09-15

  The reference study shows that magnetic nanoparticles coated with α-, β-, or γ-cyclodextrin can adsorb uremic toxins, while adsorption depends strongly on surface chemistry, incubation time, and solution composition rather than toxin concentration alone. Its quantitative mass-spectrometry workflow provides a useful framework for evaluating protein-bound toxin removal and for designing future blood-compatible adsorbent systems.

• WST-8 Glucose Uptake Assay: Delivery Biology

  2026-09-14

  Learn how the WST-8 Glucose Uptake Assay Kit can serve as a functional metabolic readout in cell-penetrating peptide and nucleic acid delivery studies. This article connects ion-dependent nanoparticle behavior with glucose handling while clarifying assay design, controls, and interpretation limits.

8102 records 1/541 page Next 12345 下5页 Last page